Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome
Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome
复制标题
DOI：
10.1086/500469
复制
发表时间：
2006-03-15
影响因子：
6.4
通讯作者：
Cao, WC
中科院分区：
文献类型：
--
作者：
Liu, W;Fontanet, A;Cao, WC
采用酶联免疫吸附试验和中和试验对56例严重急性呼吸综合征（SARS）恢复期患者发病后1、4、7、10、16和24个月血清中抗SARS冠状病毒IgG抗体和中和抗体滴度进行了检测。IgG抗体和NAb滴度高度相关，在发病后4个月达到峰值，此后下降。IgG抗体在所有患者中保持可检测，直到第16个月，并且在第24个月时在11.8%的患者中变得不可检测。NAb在整个随访期间保持可检测性的发现在防止再感染方面令人放心;然而，NAb滴度在16个月后显著下降。
In a cohort study of 56 convalescent patients with severe acute respiratory syndrome (SARS), titers of immunoglobulin G (IgG) antibodies and neutralizing antibodies (NAbs) against SARS-associated coronavirus were assessed at regular intervals (at 1, 4, 7, 10, 16, and 24 months after the onset of disease) by use of enzyme-linked immunosorbent assay and neutralization assay. IgG antibody and NAb titers were highly correlated, peaking at month 4 after the onset of disease and decreasing thereafter. IgG antibodies remained detectable in all patients until month 16, and they became undetectable in 11.8% of patients at month 24. The finding that NAbs remained detectable throughout follow-up is reassuring in terms of protection provided against reinfection; however, NAb titers decreased markedly after month 16.